Immunome Prices Public Offering Of 10M Common Stock At $20/Share
Author: Benzinga Newsdesk | February 14, 2024 03:38am
The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 16, 2024, subject to the satisfaction of customary closing conditions.
Posted In: IMNM